Table 2.
IgG-TrimericS antibody levels of subjects who provided a blood sample at all time points stratified by the presence or absence of abdominal obesity and SARS-CoV-2 infection status.
| With Abdominal Obesity (n = 149) | Without Abdominal Obesity (n = 362) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antibody Levels | Total (n = 511) |
Without Prior SARS-CoV-2 Infection (n = 76) | With SARS-CoV-2 Infection before Vaccine (n = 34) |
SARS-CoV-2 Infection after Vaccine (n = 39) |
p-Value | Without SARS-CoV-2 Infection (n = 186) | With SARS-CoV-2 Infection before Vaccine (n = 75) | SARS-CoV-2 Infection after Vaccine (n = 101) |
p-Value |
| Baseline | 9.67 ± 1.40 n = 90 |
4.81 n = 11 |
98.93 ± 74.44 n = 6 |
4.81 n = 8 |
<0.0001 *° |
5.59 ± 0.58 n = 32 |
71.81 ± 24.26 n = 13 |
6.11 ± 1.19 n = 20 |
<0.0001 *° |
| 21 days after dose 1 |
680.84 ± 49.58 | 274.16 ± 36.40 | 7511.83 ± 1895.77 | 333.58 ± 61.94 | <0.0001 *° |
362.54 ± 26.99 | 7872.56 ± 931.04 | 410.72 ± 32.39 | <0.0001 *° |
| 1 month after dose 2 |
2837.32 ± 110.30 | 1773.18 ± 155.93 | 7420.51 ± 1296.00 | 2130.24 ± 231.39 | <0.0001 *° |
2399.17 ± 123.48 | 6562.31 ± 631.09 | 2386.67 ± 156.08 | <0.0001 *° |
| 3 months after dose 2 |
1035.22 ± 43.80 | 575.90 ± 53.28 | 2985.81 ± 550.26 | 672.12 ± 68.08 | <0.0001 *° |
892.48 ± 44.54 | 2868.23 ± 308.43 | 820.87 ± 60.84 | <0.0001 *° |
| 6 months after dose 2 |
463.96 ± 21.32 | 267.78 ± 14.63 | 1335.15 ± 267.46 | 296.44 ± 30.03 | <0.0001 *° |
391.60 ± 22.71 | 1431.65 ± 155.39 | 358.84 ± 29.21 | <0.0001 *° |
| 9 months after dose 2 |
243.18 ± 11.93 | 126.78 ± 14.62 | 746.25 ± 131.40 | 183.41 ± 32.79 | <0.0001 *° |
176.38 ± 10.74 | 847.73 ± 92.92 | 216.88 ± 17.25 | <0.0001 *° |
| 1 month after booster dose |
6218.25 ± 237.47 | 6470.55 ± 695.82 | 6413.54 ± 832.40 | 6850.16 ± 947.21 | 0.8892 | 7561.64 ± 406.80 | 4521.62 ± 429.76 | 5084.36 ± 500.43 | <0.0001 #* |
| 3 months after booster dose |
4175.81 ± 181.19 | 2943.17 ± 335.19 | 4692.80 ± 854.60 | 8791.71 ± 1246.30 | <0.0001 #° |
3346.92 ± 208.06 | 3345.35 ± 314.00 | 6944.18 ± 682.39 | <0.0001 #° |
Abdominal obesity (waist circumference ≥ 102 cm for men, ≥88 cm for women); no abdominal obesity (waist circumference < 102 cm for men, <88 cm for women). * (SARS-CoV-2 infection before vaccine vs. no prior SARS-CoV-2 infection) # (SARS-CoV-2 infection after vaccine vs. no prior SARS-CoV-2 infection) ° (SARS-CoV-2 infection before vaccine vs. SARS-CoV-2 infection after vaccine).